TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

MARCAINE

BUPIVACAINE HYDROCHLORIDE
Approved 1984-05-04
1
Indication
--
Phase 3 Trials
41
Years on Market

Details

Status
Prescription
First Approved
1984-05-04
Routes
SPINAL
Dosage Forms
INJECTABLE

Companies

Active Ingredient: BUPIVACAINE HYDROCHLORIDE

MARCAINE Approval History

Loading approval history...

What MARCAINE Treats

1 FDA approvals

Originally approved for its first indication in 1984 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MARCAINE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Marcaine® 0.5% (5 mg/mL) with epinephrine 1:200,000 injection is indicated for the production of local anesthesia for dental procedures by infiltration injection or nerve block in adults. Marcaine® 0.5% (5 mg/mL) with epinephrine 1:200,000 injection is not recommended for children.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.